Glenmark Pharmaceuticals is currently trading at Rs. 209.50, up by 17.65 points or 9.21% from its previous closing of Rs. 191.70 on the BSE.
The scrip opened at Rs. 199.00 and has touched a high and low of Rs. 215.95 and Rs. 192.10 respectively. So far 143457 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 667.00 on 29-Mar-2019 and a 52 week low of Rs. 168.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 218.50 and Rs. 184.00 respectively. The current market cap of the company is Rs. 5898.73 crore.
The promoters holding in the company stood at 46.59%, while Institutions and Non-Institutions held 37.20% and 16.21% respectively.
Glenmark Pharmaceuticals has entered into an agreement with Hindustan Unilever (HUL) for divestment of its VWash brand and other extensions. Under this agreement, the brand and other trademarks, copyrights, know-how associated with Glenmark's VWash business will be transferred to HUL.
Glenmark will receive an upfront payment and royalty on sales for 3 years. No employees will be transferred as a part of this agreement. The transaction is expected to be completed in the next few months subject to customary approvals.
Glenmark Pharmaceuticals (Glenmark) is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
